Live
FierceBiotechBioNTech, SynOx plot paths to FDA as trials hit goals in competitive tumor typesFierceBiotechIdeaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trialFierceBiotechSeaport, Hemab prepare for IPO voyages to fund depression, clotting candidatesFierceBiotechRegeneron rides into radiopharma via $2.1B biobucks pact with Australia’s TelixFierceBiotechAllogene’s off-the-shelf CAR-T erases lingering lymphoma cells in early slice of dataEndpoints NewsIdeaya’s uveal melanoma drug exceeds success benchmark in late-stage trialLonza NewsBiologics Contract Manufacturing Market to Hit US$ 83.47 - openPR.comThermo FisherGoldman Sachs Adjusts PT on Thermo Fisher Scientific to $610 From $650, Maintains Buy Rating - marketscreener.comPharmaVoicePredictive analytics in pharma turns lab data into launch strategiesBioPharma DiveRethinking dermatology trial design for late-stage successBioPharma DiveConnected medical devices: Smarter care starts hereEndpoints NewsSeaport and Hemab file for IPOs, with Kailera expected to price soon
FierceBiotech Apr 13, 2026

Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial

Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial

Original
Body unavailable. Use the original source.

Directory

59 All